Antibacterial Therapeutic Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug Class, by Drug Mechanism and by Route of Administration : Global Opportunity Analysis and Industry Forecast, 2023-2032

Antibacterial drugs inhibit bacterial growth for the preventions and treatment of bacterial infections. Antibacterial antibiotic drugs represents the most remarkable portion of antibiotic therapy. The global antibacterial therapeutic market has observed tremendous growth over the past few decades owing to increasing use of antibiotics in the treatment of bacterial infections. However, the misuse or overuse of antibiotics has led to the emergence of resistant strains of bacteria. This represents the unmet market need for innovative antibacterial therapy, as rising number of infections that are complicated to treat, pose a significant public health threat. The major factors such as, increasing research and development investment and a large patient pool, are anticipated to fuel the market growth. Other factors driving the global antibacterial therapeutic market are; rising incidences of infectious diseases, high prevalence of hospital acquired infections, rising disease awareness, public and private initiatives to promote judicious use of antibiotics, improving regulatory framework, large population in the emerging economies with compromised health environment, and the increasing count of geriatric population. However, ambiguous reimbursement scenario, and limited accessibility of drugs in emerging economies are likely to restrict the market growth.

The global antibacterial therapeutic market is segmented on the basis of drug class, drug mechanism, route of administration and geography. According to drug type, the market is segmented into; Penicillins, Cephalosporins, Quinolone, Aminoglycosides, Monobactams, Carbapenems, Macrolides and Others. On the basis of drug mechanism the market is segmented into; Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, Nucleic Acid Inhibitors, Folic Acid synthesis inhibitors and Mycolic Acid synthesis inhibitors. The market is also segmented on the basis of route of administration into oral, topical and parenteral. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA. New product approval is the key strategy adopted by top industry players. For instance, FDA has recently approved Dalvance, an intravenous antibacterial drug intended for the treatment of skin infections caused by Staphylococcus aureus. Similarly in Dec 2014, Cubist Pharmaceuticals, received the FDA approval for Zerbaxa, a combination of ceftolozan and tazobactam antibacterial drugs intended for use in intra-abdominal and urinary tract infections. The companies profiled in this report include, Abbott Laboratories, Daiichi Sankyo Company, Limited, Pfizer, Inc., Takeda Pharmaceutical Company Ltd, Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca plc, Bayer AG and Merck & Co., Inc.

KEY MARKET BENEFITS:

• Comprehensive analysis of factors that drive and restrict the growth of the global antibacterial therapeutic market is provided
• The report provides a comprehensive analysis of the current market and estimations which would enable the stakeholders to capitalize on prevailing market opportunities
• An in-depth analysis of key segments of the market demonstrate the types of Drug Classes along with along with drug mechanisms and routes of administration in the global antibacterial therapeutic market
• SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
• Region-wise antibacterial therapeutic market scenario is comprehensively analysed in the report

  Antibacterial Therapeutic Market Report Highlights

Aspects	Details
By Drug Class	Penicillins Cephalosporins Quinolone Aminoglycosides Monobactams Carbapenems Macrolides Others
By Drug Mechanism	Cell Wall Synthesis inhibitors Protein Synthesis inhibitors Nucleic Acid inhibitors Folic Acid synthesis inhibitors Mycolic Acid synthesis inhibitors
By Route of Administration	Oral Topical Parenteral Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)